Co-Authors
This is a "connection" page, showing publications co-authored by Jeffrey Sparks and Rebecca Grainger.
Connection Strength
0.695
-
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
Score: 0.237
-
Reply. Arthritis Rheumatol. 2021 09; 73(9):1767-1768.
Score: 0.060
-
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatol. 2021 Oct; 3(10):e707-e714.
Score: 0.060
-
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021 03; 73(3):374-380.
Score: 0.058
-
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 07; 80(7):930-942.
Score: 0.058
-
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. Arthritis Rheumatol. 2021 01; 73(1):36-47.
Score: 0.057
-
Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Semin Arthritis Rheum. 2020 10; 50(5):1191-1201.
Score: 0.056
-
Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist. Ann Rheum Dis. 2020 06; 79(6):734-736.
Score: 0.055
-
A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Ann Intern Med. 2020 06 16; 172(12):819-821.
Score: 0.055